Please click here to log in with you RCPsych web account details; you will be redirected back to CPD Online.If you have forgotten your College web account details, you will be able to reset them here.
Please click here to log in if your institution has a subscription to CPD Online with Athens access.
Please click here to log in if you are subscribed through Medicom Netherlands.
If you having troubles signing in with the options above, please try this alternative login route.
Module home
Module introduction
Module information
Related articles: Advances in Psychiatric Treatment
About the authors
Pre-module test
Section 1: Introduction and epidemiology
(1.1) Section 1: Introduction and epidemiology
(1.2) Introduction and epidemiology
(1.3) Introduction and epidemiology
(1.4) Epidemiology of stimulant misuse
(1.5) Interactive exercise: epidemiology of stimulant misuse
(1.6) Section 1: Recap
(1.7) Section 1: Summary
Section 2: Cocaine and crack cocaine
(2.1) Section 2: Cocaine and crack cocaine
(2.2) Difference between cocaine and crack cocaine
(2.3) Cocaine: misuse among the general population
(2.4) Reflection
(2.5) Reflection: answer
(2.6) Crack cocaine: misuse among the general population
(2.7) Cocaine: misuse among young adults
(2.8) Patterns of use and socio-demographics
(2.9) Profiles of cocaine users
(2.10) Treatment demand indicator
(2.11) Reflection
(2.12) Reflection: answer
(2.13) Cocaine-related deaths
(2.14) Section 2: Recap
(2.15) Section 2: Summary
Section 3: Amphetamine, methamphetamine and ecstasy
(3.1) Section 3: Amphetamine, methamphetamine and ecstasy
(3.2) Interactive exercise: definitions
(3.3) Amphetamine, methamphetamine and ecstasy: misuse among the general population
(3.4) Amphetamine and methamphetamine: misuse among young adults
(3.5) Amphetamine and methamphetamine: treatment demand indicator
(3.6) Amphetamine- and methamphetamine-related deaths
(3.7) Ecstasy: misuse among the general population
(3.8) Reflection
(3.9) Reflection: answer
(3.10) Ecstasy: misuse among young adults
(3.11) Ecstasy: patterns of use
(3.12) Ecstasy: treatment demand indicator
(3.13) Ecstasy-related deaths
(3.14) Section 3: Recap
(3.15) Section 3: Summary
Section 4: Novel psychoactive substances
(4.1) Section 4: Novel psychoactive substances
(4.2) Novel psychoactive substances
(4.3) BZP and piperazine derivatives
(4.4) Mephedrone and cathinone derivatives
(4.5) Mephedrone and cathinone derivatives
(4.6) Mephedrone-related deaths
(4.7) Naphyrone
(4.8) 4,4-DMAR
(4.9) Methylphenidate-like NPS
(4.10) Synthetic cocaine analogs
(4.11) Section 4: Recap
(4.12) Section 4: Summary
Section 5: Stimulant misuse: impact on mental health
(5.1) Section 5: Stimulant misuse: impact on mental health
(5.2) Introduction
(5.3) Dual diagnosis
(5.4) Substance-induced psychiatric disorders
(5.5) Interactive exercise: cocaine: impact on mental health
(5.6) Cocaine: impact on mental health
(5.7) Clinical vignette: cocaine
(5.8) Amphetamines: impact on mental health
(5.9) Psychopathological consequences
(5.10) Interactive exercise: clinical signs of amphetamine intoxication
(5.11) Amphetamine-induced psychosis
(5.12) Amphetamine withdrawal symptoms
(5.13) Amphetamine neurotoxicity
(5.14) Amphetamine: clinical vignette
(5.15) Ecstasy: impact on mental health
(5.16) Psychoactive effects
(5.17) Neurocognitive problems
(5.18) Impact on serotonin levels
(5.19) Acute and long-term consequences
(5.20) Clinical vignette: ecstasy
(5.21) Mephedrone: impact on mental health
(5.22) Clinical vignette: mephedrone
(5.23) Section 5: Recap
(5.24) Section 5: Summary
Module summary
Module test
Acknowledgements
Send feedback
Useful resources
Take-home notes
References
Further reading